Specific interventions included in the review
Studies of aspirin were eligible for inclusion. The included studies obtained information on aspirin exposure mainly from interviews with mothers; the timing of these ranged from during early pregnancy to 14 months after birth. Other methods included the examination of prescriptions given to mothers, review of medical records and, in the case of a randomised controlled trial (RCT), the patients were assigned to aspirin or placebo. No information was available on the extent of aspirin exposure in the included studies.
Participants included in the review
Studies of women exposed to aspirin during the first trimester of pregnancy were eligible for inclusion. Studies were excluded if they reported significant differences between the women exposed to aspirin and the control group, such as treatment with other drug therapies in the exposed group but not the control group.
Outcomes assessed in the review
Studies reporting congenital malformations were eligible for inclusion, except where only premature closure of the ductus arterious was reported as a primary outcome. The included studies reported on the overall rates of malformation, central nervous system (CNS) defects, congenital heart defects, gastroschisis and other congenital anomalies. The included studies obtained information on congenital malformation from a wide range of sources including a review of hospital charts, clinical examination (ranging from 3 days after birth to first year of life) and a register of congenital malformations.
How were decisions on the relevance of primary studies made?
One reviewer carried out a preliminary screening of the searches. Two reviewers then independently screened the selected articles and any disagreements were resolved by recourse to a third reviewer.
Assessment of study quality
The authors did not state that they assessed validity.
Data extraction
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Two reviewers independently extracted the data into 2x2 tables and resolved any discrepancies by consensus.
Methods of synthesis
How were the studies combined?
The pooled odds ratio (OR) and 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel randomeffects model.
How were differences between studies investigated?
The chi-squared test was used to investigate statistical heterogeneity between the studies. For some of the analyses the studies were stratified according to study design. A sensitivity analysis was used to examine the effect of specific studies on the pooled OR.
Results of the review
Twenty-two studies were included: 1 RCT, 6 cohort studies and 15 case-control studies (the number of participants was not reported for all studies).
Overall rates of malformation (1 RCT, 5 cohort and 2 case-control studies; 16,138 exposed participants and 49,890 control participants).
The overall risk of congenital malformation was not statistically significantly higher in the offspring of women exposed to aspirin in the first trimester of pregnancy compared with control participants (OR 1.33, 95% CI: 0.94, 1.89). There was statistically significant heterogeneity (P=0.016); the authors reported separate analyses of the case-control studies alone and the cohort studies together with the RCT.
CNS defects (3 case-control and 1 cohort study).
The risk of congenital CNS defects was not statistically significantly higher in the offspring of women exposed to aspirin compared with control participants (OR 1.39, 95% CI: 0.89, 2.16). There was statistically significant heterogeneity P=0.054); the authors reported a separate analysis of the case-control studies only.
Neural tube defects (3 case-control studies).
The risk of neural tube defects was not statistically significantly higher in the offspring of women exposed to aspirin compared with control participants (OR 2.2, 95% CI: 0.93, 5.17). There was statistically significant heterogeneity (P=0.002). The analysis was repeated after excluding one atypical study.
Congenital heart defects (4 case-control and 2 cohort studies). The risk of congenital heart defects was not statistically significantly higher in the offspring of women exposed to aspirin compared with control participants (OR 1.01, 95% CI: 0.91, 1.12).
Gastroschisis (5 case-control studies).
The risk of gastroschisis was significantly increased in the offspring of women exposed to aspirin compared with control participants (OR 2.37, 95% CI: 1.44, 3.88).
The authors reported further data on congenital anomalies that were reported in only single studies or in only two studies.
Authors' conclusions
There was no evidence of an overall increased risk of congenital malformations that could be associated with aspirin use during the first trimester of pregnancy, although aspirin exposure during the first trimester may be associated with an increased risk of gastroschisis.
